GEFTIB 250MG TABLET

Price 3662 INR/ Thousand

Get a Price/Quote

MOQ : 5 Bottles

GEFTIB 250MG TABLET Specification

Salt Composition
Gefitinib 250mg

Origin of Medicine
India

Indication
Treatment of locally advanced or metastatic non-small cell lung cancer with EGFR mutations

Pacakaging (Quantity Per Box)
30 Tablets

Dosage Form
Oral Tablet

Drug Type
Targeted therapy

Ingredients
Gefitinib

Physical Form
Tablets

Function
Antineoplastic (cancer treatment)

Recommended For
Non-Small Cell Lung Cancer Patients

Dosage
250mg once daily or as directed by physician

Dosage Guidelines
As prescribed by the oncologist

Suitable For
Adults

Quantity
30 tablets per box

Storage Instructions
Store below 30C, protect from moisture and light

MRP
As per pack

Therapeutic Category
Anticancer agents

Prescription/Non Prescription
Prescription

Marketed By
Glenmark Pharmaceuticals Ltd.

Route of Administration
Oral

Appearance
Film-coated tablet

Packaging Type
Blister strips in carton

Side Effects
Nausea, diarrhea, rash, loss of appetite, dry skin

Caution
To be sold by retail on the prescription of an oncologist only.

ATC Code
L01EB01

Colour
Brown

Shelf Life
24 months from date of manufacture

Trade Name
GEFTIB 250MG TABLET

About GEFTIB 250MG TABLET

GEFITINIB TABLET Geftib Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.Geftib Tablet can be taken with or without food, but better to have it same time every day for better results. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.The most common side effects of this medicine include nausea, rash, vomiting and weight loss. It may cause severe diarrhea, drink plenty of fluids or consult with your doctor if it bothers you. It makes you sensitive towards sunlight, hence wear protective clothing or use sunscreen while going out. In case you develop ulceration in mouth, changes in your vision, or breathing difficulties than it is better to inform the doctor. Your doctor may advise for regular monitoring of liver function while you are taking this medicine.Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. If you have to take an antacid or any other medicine, take it at a gap of at least 2 hours after taking the cancer medicine.

Targeted Cancer Therapy

GEFTIB 250MG TABLET employs Gefitinib as its active ingredient, providing targeted therapy for non-small cell lung cancer patients with EGFR mutations. This therapy is designed to inhibit specific cancer cell growth, improving treatment outcomes and offering specialized care for those diagnosed with advanced lung cancer.

Convenient Oral Administration

Administered orally, GEFTIB 250MG TABLET offers convenience in cancer treatment. Each tablet is film-coated for easier ingestion and is intended for adult patients. Taking one tablet daily-under guidance from an oncologist-simplifies the treatment process while ensuring precise dosage.

Stringent Prescription and Storage Guidelines

GEFTIB 250MG TABLET must be dispensed only on the prescription of an oncologist, reflecting its specific therapeutic use and potential side effects. Patients and healthcare providers should store the medication below 30C, protected from light and moisture, to maintain its efficacy throughout its 24-month shelf life.

FAQ's of GEFTIB 250MG TABLET:

Q: How should GEFTIB 250MG TABLET be taken for optimal effectiveness?

A: GEFTIB 250MG TABLET should be swallowed whole with water once daily, exactly as directed by your oncologist. Follow prescribed instructions to ensure the medication targets cancer cells efficiently.

Q: What is the main benefit of using GEFTIB 250MG TABLET in cancer treatment?

A: The tablet provides targeted therapy for non-small cell lung cancer patients with EGFR mutations, potentially inhibiting cancer cell growth while minimizing effects on healthy cells compared to conventional chemotherapy.

Q: When should GEFTIB 250MG TABLET be used in lung cancer management?

A: This medication is indicated for adults with locally advanced or metastatic non-small cell lung cancer confirmed to have EGFR mutations. Usage should begin and continue as prescribed by an oncologist.

Q: Where and how should GEFTIB 250MG TABLET be stored to preserve quality?

A: Store the tablets below 30C, away from moisture and direct light, preferably in their original carton and blister packaging. This ensures the medicine maintains its effectiveness throughout the shelf life.

Q: What are the common side effects of GEFTIB 250MG TABLET, and what should I do if they occur?

A: Common side effects include nausea, diarrhea, loss of appetite, rash, and dry skin. If you experience persistent or severe symptoms, contact your oncologist promptly for guidance on managing these effects.

Q: What process is involved in obtaining GEFTIB 250MG TABLET?

A: Only a registered oncologist can prescribe this medication. Present the prescription at a licensed pharmacy or healthcare distributor in India to obtain the tablets in blister strips.

Q: Is GEFTIB 250MG TABLET suitable for children or non-cancer patients?

A: No, GEFTIB 250MG TABLET is specifically intended for adult patients diagnosed with non-small cell lung cancer displaying EGFR mutations. It should not be used in children or individuals without a relevant oncologist's prescription.

Tell us about your requirement